Skip to main content
SpringerLink
Log in
Book cover

Toxicology of Metals pp 267–278Cite as

Metals and Anticancer Drug Resistance

  • Chapter

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 115))

Abstract

Metals have historically held a distinguished position in the Pharmacopeia. Metals, such as mercury and arsenic, were the mainstays of early physicians (WOod 1877). Today more than 80 of the known metals in the periodic table have been shown to have biological activity. Most, however, are toxic and do not have desirable therapeutic activity. Exceptions include aluminum, bismuth, gold, lithium, and platinum. Aluminum is used as an antacid, while bismuth finds employment for gastrointestinal disturbances. Gold salts are still useful for the treatment of rheumatism and lithium has become an important treatment for depression. Metals, such as zinc and iron, are also important as nutritional supplements. A number of drugs also require metals for their biological activity. For example, the anticancer agent bleomycin requires iron for its DNA cleaving and antitumor activity (LAzo and SEbti 1989). Metals can also induce gene transcription and alter protein function. Many transcription factors and enzymes require metals.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin:perspectives on mechanisms of acquired resistance. Cancer Cells 2:35–43

    PubMed  CAS  Google Scholar 

  • Andrews PA, Murphy MP, Howell SB (1987) Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 19:149–154

    Article  PubMed  CAS  Google Scholar 

  • Bahnson RR, Banner BF, Ernstoff MS, Lazo JS, Cherian MG, Banerjee D, Chin JL (1991) Immunohistochemical localization of metallothionein in transitional cell carcinoma of the bladder. J Urol 146:1518–1520

    PubMed  CAS  Google Scholar 

  • Bakka A, Endresen L, Johnsen AB, Edminson PD, Rugstad HE (1981) Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. Toxicol Appl Pharmacol 61:215–226

    Article  PubMed  CAS  Google Scholar 

  • Banerjee D, Onosaka S, Cherian MG (1982) Immunohistochemical localization of metallothionein in cell nucleus and cytoplasm of rat liver and kidney. Toxicology 24:95–105

    Article  PubMed  CAS  Google Scholar 

  • Basu A, Lazo JS (1991) Suppression of dexamethasone-induced metallothionein expression and cis-diamminedichloroplatinum(II) resistance by v-mos. Cancer Res 51:893–896

    PubMed  CAS  Google Scholar 

  • Boogaard PJ, Slikkerveer A, Nagelkerke JF, Mulder GJ (1991) The role of metallothionein in the reduction of cisplatin-induced nephrotoxicity by Bi3+-pretreatment in the rat in vivo and in vitro. Are antioxidant metallothionein more relevant than platinum binding? Biochem Pharmacol 41:369–375

    Article  PubMed  CAS  Google Scholar 

  • Doz F, Berens ME, Deschepper CF, Dougherty DV, Bigornia V, Barker M, Rosenblum ML (1992) Experimental basis for increasing the therapeutic index of cis-diamminedicarboxylatocyclobutaneplatinum(II) in brain tumor therapy by a high-zinc diet. Cancer Chemother Pharmacol 29:219–226

    Article  PubMed  CAS  Google Scholar 

  • Ehrenfeld GM, Shipley JB, Heimbrook DC, Sugiyama H, Long EC, van Boom JH, van der Marel GA, Oppenheimer NJ, Hecht SM (1987) Copper-dependent cleavage of DNA by bleomycin. Biochemistry 26:931–942

    Article  PubMed  CAS  Google Scholar 

  • Eichholtz-Wirth H, Born R, Reidel G, Hietel B (1993) Transient cisplatin-resistant murine fibrosarcoma cell characterized by increased metallothionein content. J Cancer Res clin Oncol 119:227–233

    Article  PubMed  CAS  Google Scholar 

  • Endresen L, Rugstad HE (1987) Protective function of metallothionein against certain anticancer agents. Experientia 52:595–602

    CAS  Google Scholar 

  • Endresen L, Bakka A, Rugstad HE (1983) Increased resistance to chlorambucil in cultured cells with a high concentration of cytoplasmic metallothionein. Cancer Res 43:2918–2926

    PubMed  CAS  Google Scholar 

  • Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89:3070–3074

    Article  PubMed  CAS  Google Scholar 

  • Hagenbeek A, Philip T, Bron D, Guglielmi C, Coiffier B, Gisselbrecht C, Kluin Nelemans JC, Somers T, Misset JL, Van der Lely J et al. (1991) The Parma international randomized study in relapsed non Hodgkin lymphoma:1st interim analysis of 128 patients (as 15 January 1991:153 patients). Bone Marrow Transplant 7 [Suppl] 2:142

    Google Scholar 

  • Hannun YA, Foglesong RJ, Bell RM (1989) The adriamycin-iron(III) complex is a potent inhibitor of protein kinase C. J Biol Chem 264:9960–9966

    PubMed  CAS  Google Scholar 

  • Imura N, Satoh M, Nagaruma A (1992) Possible application of metallothionein in cancer therapy. In:Klassen CD, Suzuki KT (eds) Metallothioneins in biology and medicine. CRC, Boca Raton, pp 375–382

    Google Scholar 

  • Isonishi S, Horn DK, Thiebaut FB, Mann SC, Andrews PA, Basu A, Lazo JS, Eastman A, Howell SB (1991) Expression of the c-Ha-ras oncogene in mouse NIH3T3 cells induces resistance to cisplatin. Cancer Res 51:5903–5909

    PubMed  CAS  Google Scholar 

  • Kaina B, Lohrer H, Karin M, Herrlich P (1990) Overexpressed human metallothionein IIA gene protects Chinese hamster ovary cells from killing by alkylating agents. Proc Natl Acad Sci USA 87:2710–2714

    Article  PubMed  CAS  Google Scholar 

  • Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T, Saijo N (1991) Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51:3237–3242

    PubMed  CAS  Google Scholar 

  • Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS (1988) Over-expression of metallothionein confers resistance to anticancer drugs. Science 241:1813–1815

    Article  PubMed  CAS  Google Scholar 

  • Kelley J, Kovacs EJ, Nicholson K, Fabisiak JP (1991) Transforming growth factor-beta production by lung macrophages and fibroblasts. Chest 99:85S–86S

    PubMed  CAS  Google Scholar 

  • Kondo Y, Satoh M, Imura N, Akimoto M (1991) Effect of bismuth nitrate given in combination with cis-diamminedichloroplatinum(II) on the antitumor activity and renal toxicity of the latter in nude mice inoculated with human bladder tumor. Cancer Chemother Pharmacol 29:19–23

    Article  PubMed  CAS  Google Scholar 

  • Koropatnick J, Pearson J (1990) Zinc treatment, metallothionein expression, and resistance to cisplatin in mouse melanoma cells. Somat Cell Mol Genet 16:529–537

    Article  PubMed  CAS  Google Scholar 

  • Kraker A, Schmidt J, Krezoski S, Petering DH (1985) Binding of cis-dichlorodiammine platinum(II) to metallothionein in Ehrlich cells. Biochem Biophys Res Commun 130:786–792

    Article  PubMed  CAS  Google Scholar 

  • Lazo JS, Basu A (1991) Metallothionein expression and transient resistance to electrophilic antineoplastic drugs. Semin Cancer Biol 2:267–271

    PubMed  CAS  Google Scholar 

  • Lazo JS, Sebti SM (1989) Malignant cell resistance to bleomycin to bleoymycin-group antibiotics. In: Kessel D (ed) Anticancer drug resistance. CRC, Boca Raton, pp 276–279

    Google Scholar 

  • Lyman S, Ujjani B, Renner K, Antholine W, Petering DH, Whetstone JW, Knight JM (1986) Properties of the initial reaction of bleomycin and several of its metal complexes with Ehrlich cells. Cancer Res 46:4472–4478

    PubMed  CAS  Google Scholar 

  • Mattern J, Volm M (1992) Increased resistance to doxorubicin in human non-small cell lung carcinomas with metallothionein expression. Int J Oncol 1:687–689

    PubMed  CAS  Google Scholar 

  • Murphy D, McGown AT, Crowther D, Mander A, Fox BW (1991) Metallothionein levels in ovarian tumours before and after chemotherapy. Br J Cancer 63:711–714

    Article  PubMed  CAS  Google Scholar 

  • Myers C, Gianni L, Zweier J, Muindi J, Sinha BK, Eliot H (1986) Role of iron in adriamycin biochemistry. Fed Proc 45:2792–2797

    PubMed  CAS  Google Scholar 

  • Naganuma A, Satoh M, Koyama Y, Imura N (1985) Protective effect of metallothionein inducing metals on lethal toxicity of cis-diamminedichloroplatinum in mice. Toxicol Lett 24:203–207

    Article  PubMed  CAS  Google Scholar 

  • Naganuma A, Satoh M, Imura N (1987) Prevention of lethal and renal toxicity of cis- diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice. Cancer Res 47:983–987

    PubMed  CAS  Google Scholar 

  • Naganuma A, Satoh M, Imura N (1988) Specific reduction of toxic side effects of adriamycin by induction of metallothionein in mice. Jpn J Cancer Res 79:406–411

    Article  PubMed  CAS  Google Scholar 

  • Nartey N, Cherian MG, Banerjee D (1987) Immunohistochemical localization of metallothionein in human thyroid tumors. Am J Pathol 129:177–182

    PubMed  CAS  Google Scholar 

  • Pattanaik A, Bachowski G, Laib J, Lemkuil D, Shaw CF III, Petering DH, Hitchcock A, Saryan L (1992) Properties of the reaction of cis-dichlorodiammine- platinum(II) with metallothionein. J Biol Chem 267:16121–16128

    PubMed  CAS  Google Scholar 

  • Satoh M, Naganuma A, Imura N (1988) Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination. Cancer Chemother Pharmacol 21:176–178

    Article  PubMed  CAS  Google Scholar 

  • Satoh M, Kloth DM, Kadhim SA, Chin JL, Naganuma A, Imura N, Cherian MG (1993) Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis. Cancer Res 53:1829–1832

    PubMed  CAS  Google Scholar 

  • Satomi N, Sakurai A, Haranaka R, Haranaka K (1988) Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor. J Biol Response Mod 7:54–64

    PubMed  CAS  Google Scholar 

  • Schilder RJ, Hall L, Monks A, Handel LM, Fornace AJ Jr, Ozols RF, Fojo AT, Hamilton TC (1990) Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 45:416–422

    Article  PubMed  CAS  Google Scholar 

  • Sharma RP, Edwards IR (1983) Cisplatinum:subcellular distribution and binding to cytosolic ligands. Biochem Pharmacol 32:2665–2669

    Article  PubMed  CAS  Google Scholar 

  • Sherman SE, Lippard SJ (1987) Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev 87:1153–1181

    Article  CAS  Google Scholar 

  • Shimizu T, Kubota M, Tanizawa A, Sano H, Kasai Y, Hashimoto H, Akiyama Y, Mikawa H (1990) Inhibition of both etoposide-induced DNA fragmentation and activation of poly ( ADP-ribose) synthesis by zinc ion. Biochem Biophys Res Commun 169:1172–1177

    Article  PubMed  CAS  Google Scholar 

  • Sommer S, Thorling EB, Jakobsen A, Steiness E, Ostergaard K (1989) Can bismuth decrease the kidney toxic effect of cis-platinum? Eur J Cancer Clin Oncol 25:1903–1904

    Article  PubMed  CAS  Google Scholar 

  • Tobey RA, Enger MD, Griffith JK, Hildebrand CE (1982) Zinc-induced resistance to alkylating agent toxicity. Cancer Res 42:2980–2984

    PubMed  CAS  Google Scholar 

  • Webber MM, Rehman SM, James GT (1988) Metallothionein induction and deinduction in human prostatic carcinoma cells:relationship with resistance and sensitivity to adriamycin. Cancer Res 48:4503–4508

    PubMed  CAS  Google Scholar 

  • Wood HC Jr (1877) A treatise on therapeutics comprising materia medica and toxicology, 2nd edn. JB Lipincott, Philadelphia, pp 351–384

    Google Scholar 

  • Yang YY, Kuo SM, DeFilippo JM, Saijo N, Lazo JS (1994) Metallothionein isoform content and gene expression in cisplatin sensitive and resistant human small cell lung carcinomas. Proc Am Assoc Cancer Res 33:2766

    Google Scholar 

  • Zelazowski AJ, Garvey JS, Hoeschele JD (1984) In vivo and in vitro binding of platinum to metallothionein. Arch Biochem Biophys 229:246–252

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. S. Lazo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology, University of Western Ontario, N6A 5C1, Ontario, Canada

    Robert A. Goyer M.D. (Professor Emeritus) & M. George Cherian Ph.D. (Professor) (Professor Emeritus) &  (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lazo, J.S. (1995). Metals and Anticancer Drug Resistance. In: Goyer, R.A., Cherian, M.G. (eds) Toxicology of Metals. Handbook of Experimental Pharmacology, vol 115. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79162-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79162-8_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-79164-2

  • Online ISBN: 978-3-642-79162-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation